United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time. During the webcast, Steven D. Nathan, M.D., Schar Chair, Advanced Lung Disease and Lung Tran. ...